Healthy Upside Potential: VBI Vaccines Inc. (VBIV)

VBI Vaccines Inc. (NASDAQ: VBIV) stock jumped 0.03% on Friday to $0.60 against a previous-day closing price of $0.60. With 0.86 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.0 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6300 whereas the lowest price it dropped to was $0.5851. The 52-week range on VBIV shows that it touched its highest point at $2.02 and its lowest point at $0.36 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at 1.81.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VBIV was up-trending over the past week, with a rise of 14.57%, but this was up by 43.30% over a month. Three-month performance dropped to -6.53% while six-month performance fell -35.84%. The stock lost -67.44% in the past year, while it has gained 54.00% so far this year. A look at the trailing 12-month EPS for VBIV yields -0.43 with Next year EPS estimates of -0.26. For the next quarter, that number is -0.07. This implies an EPS growth rate of -29.20% for this year and 24.20% for next year.

Float and Shares Shorts:

At present, 258.26 million VBIV shares are outstanding with a float of 204.57 million shares on hand for trading. On Oct 13, 2022, short shares totaled 13.93 million, which was 5.39% higher than short shares on Sep 14, 2022. In addition to Mr. Jeffery R. Baxter F.C.M.A., FCMA as the firm’s Pres, CEO & Director, Mr. Christopher McNulty serves as its CFO, Head of Bus. Devel. & Director.


Institutional Ownership:

Through their ownership of 46.21% of VBIV’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.43% of VBIV, in contrast to 34.16% held by mutual funds. Shares owned by individuals account for 26.24%. As the largest shareholder in VBIV with 20.27% of the stake, Perceptive Advisors LLC holds 52,335,002 shares worth 52,335,002. A second-largest stockholder of VBIV, SSgA Funds Management, Inc., holds 12,372,113 shares, controlling over 4.79% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in VBIV, holding 12,263,293 shares or 4.75% stake. With a 1.60% stake in VBIV, the iShares Russell 2000 ETF is the largest stakeholder. A total of 4,141,561 shares are owned by the mutual fund manager. The iShares Russell 2000 Value ETF, which owns about 0.76% of VBIV stock, is the second-largest Mutual Fund holder. It holds 1,967,237 shares valued at 0.77 million. General American Investors Fund holds 0.73% of the stake in VBIV, owning 1,877,497 shares worth 0.73 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VBIV since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VBIV analysts setting a high price target of $6.00 and a low target of $2.00, the average target price over the next 12 months is $4.00. Based on these targets, VBIV could surge 900.0% to reach the target high and rise by 233.33% to reach the target low. Reaching the average price target will result in a growth of 566.67% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VBIV will report FY 2022 earnings on 03/04/2024. Analysts have provided yearly estimates in a range of -$0.27 being high and -$0.40 being low. For VBIV, this leads to a yearly average estimate of -$0.34. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. VBI Vaccines Inc. surprised analysts by -$0.01 when it reported -$0.09 EPS against a consensus estimate of -$0.08. The surprise factor in the prior quarter was -$0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.06 and the low estimate is -$0.08. The average estimate for the next quarter is thus -$0.07.

Summary of Insider Activity:

Insiders traded VBIV stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *